JP6748074B2 - バクテリオファージの改変 - Google Patents
バクテリオファージの改変 Download PDFInfo
- Publication number
- JP6748074B2 JP6748074B2 JP2017518842A JP2017518842A JP6748074B2 JP 6748074 B2 JP6748074 B2 JP 6748074B2 JP 2017518842 A JP2017518842 A JP 2017518842A JP 2017518842 A JP2017518842 A JP 2017518842A JP 6748074 B2 JP6748074 B2 JP 6748074B2
- Authority
- JP
- Japan
- Prior art keywords
- phage
- region
- target
- phi33
- bacteriophage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001515965 unidentified phage Species 0.000 title claims description 90
- 230000004048 modification Effects 0.000 title description 8
- 238000012986 modification Methods 0.000 title description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 110
- 239000000835 fiber Substances 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 53
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 44
- 230000002101 lytic effect Effects 0.000 claims description 35
- 239000003550 marker Substances 0.000 claims description 35
- 210000004899 c-terminal region Anatomy 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 230000027455 binding Effects 0.000 claims description 30
- 101710166729 Tail fiber protein Proteins 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 27
- 230000001580 bacterial effect Effects 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 23
- 210000004897 n-terminal region Anatomy 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 108091029865 Exogenous DNA Proteins 0.000 claims description 19
- 108020003175 receptors Proteins 0.000 claims description 19
- 102000005962 receptors Human genes 0.000 claims description 19
- 238000005215 recombination Methods 0.000 claims description 19
- 230000006798 recombination Effects 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 11
- 108700026220 vif Genes Proteins 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 7
- 230000003362 replicative effect Effects 0.000 claims description 5
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 claims description 4
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 claims description 4
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 claims description 4
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 claims description 4
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 claims description 4
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 claims description 4
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 claims description 4
- 230000010354 integration Effects 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 101100455520 Streptomyces lasalocidi lsd19 gene Proteins 0.000 claims description 2
- 101150037483 bkdA gene Proteins 0.000 claims description 2
- -1 fda Proteins 0.000 claims description 2
- 101150078665 lasB gene Proteins 0.000 claims description 2
- 101150084945 pdhA gene Proteins 0.000 claims description 2
- 101150078369 rpsB gene Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 4
- 102100033717 Retroviral-like aspartic protease 1 Human genes 0.000 claims 2
- 101100447530 Dictyostelium discoideum gpi gene Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 101100120969 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) pgi1 gene Proteins 0.000 claims 1
- 101150053253 pgi gene Proteins 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 60
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 45
- 241000588724 Escherichia coli Species 0.000 description 33
- 230000000295 complement effect Effects 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 18
- 238000010276 construction Methods 0.000 description 17
- 241000194107 Bacillus megaterium Species 0.000 description 13
- 101150009573 phoA gene Proteins 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 8
- 238000012239 gene modification Methods 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000007505 plaque formation Effects 0.000 description 8
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000004098 Tetracycline Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 229960002180 tetracycline Drugs 0.000 description 7
- 229930101283 tetracycline Natural products 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 150000003522 tetracyclines Chemical class 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 101150026476 PAO1 gene Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000002887 multiple sequence alignment Methods 0.000 description 6
- 101150025220 sacB gene Proteins 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 210000004215 spore Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000002457 bidirectional effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 244000078673 foodborn pathogen Species 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002925 A-like Anatomy 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 241000701867 Enterobacteria phage T7 Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- BUAQBZPEZUPDRF-RHQZKXFESA-N (2r,3r,4r,5r,6s)-2-(hydroxymethyl)-6-[(2-hydroxy-7,8,9,10-tetrahydro-6h-benzo[c]chromen-3-yl)oxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1C(CCCC1)=C1CO2 BUAQBZPEZUPDRF-RHQZKXFESA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108700023313 Bacteriophage Receptors Proteins 0.000 description 2
- 101100465058 Caenorhabditis elegans prk-2 gene Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101000708358 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 23.3 kDa protein in lys 3'region Proteins 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004666 bacterial spore Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000001320 lysogenic effect Effects 0.000 description 2
- 230000028744 lysogeny Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 101150080758 tonB gene Proteins 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101710192508 30S ribosomal protein S2 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010023798 Charybdotoxin Proteins 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 101000773038 Human herpesvirus 7 (strain RK) U21 glycoprotein Proteins 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 1
- 108050006183 Pyruvate dehydrogenase E1 component Proteins 0.000 description 1
- 102000026183 Pyruvate dehydrogenase E1 component Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101150018840 SPM1 gene Proteins 0.000 description 1
- 101100335888 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAL83 gene Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710194518 T4 protein Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000001066 phage therapy Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 101150100021 soxR gene Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 101150118060 trxA gene Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10141—Use of virus, viral particle or viral elements as a vector
- C12N2795/10144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1417810.7 | 2014-10-08 | ||
| GBGB1417810.7A GB201417810D0 (en) | 2014-10-08 | 2014-10-08 | Modifying bacteriophage |
| PCT/EP2015/073296 WO2016055586A1 (en) | 2014-10-08 | 2015-10-08 | Modifying bacteriophage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529868A JP2017529868A (ja) | 2017-10-12 |
| JP2017529868A5 JP2017529868A5 (enExample) | 2019-04-11 |
| JP6748074B2 true JP6748074B2 (ja) | 2020-08-26 |
Family
ID=51947056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518842A Active JP6748074B2 (ja) | 2014-10-08 | 2015-10-08 | バクテリオファージの改変 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10953052B2 (enExample) |
| EP (1) | EP3201323B1 (enExample) |
| JP (1) | JP6748074B2 (enExample) |
| AU (1) | AU2015329959B2 (enExample) |
| CA (1) | CA2963690A1 (enExample) |
| DK (1) | DK3201323T3 (enExample) |
| ES (1) | ES2768773T3 (enExample) |
| GB (1) | GB201417810D0 (enExample) |
| HR (1) | HRP20200171T1 (enExample) |
| HU (1) | HUE047552T2 (enExample) |
| LT (1) | LT3201323T (enExample) |
| PL (1) | PL3201323T3 (enExample) |
| PT (1) | PT3201323T (enExample) |
| SI (1) | SI3201323T1 (enExample) |
| WO (1) | WO2016055586A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417810D0 (en) | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifying bacteriophage |
| GB2544957B (en) * | 2015-07-15 | 2020-05-27 | Phico Therapeutics Ltd | Modifying bacteriophage |
| ES2867029T3 (es) * | 2016-04-08 | 2021-10-20 | Phico Therapeutics Ltd | Bacteriófago modificado |
| EP3440204A1 (en) | 2016-04-08 | 2019-02-13 | Phico Therapeutics Ltd | Modifying bacteriophage |
| WO2018002940A1 (en) * | 2016-06-30 | 2018-01-04 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacteriophage variants having extended host-range, methods for preparation and uses thereof in transducing nucleic acids into hosts of interest |
| CA3219077A1 (en) * | 2021-05-12 | 2022-11-17 | Eligo Bioscience | Production of lytic phages |
| EP4499820A1 (en) | 2022-03-30 | 2025-02-05 | Hun-Ren Biological Research Centre Szeged | Metagenomic libraries |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2417188A1 (en) | 2000-07-25 | 2002-01-31 | Carl R. Merril | Bacteriophage having multiple host range |
| GB0028130D0 (en) | 2000-11-17 | 2001-01-03 | Phico Therapeutics Ltd | Polypeptide and uses thereof |
| AU2003220072A1 (en) | 2002-03-06 | 2003-09-22 | Musc Foundation For Research Development | Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria |
| GB0314469D0 (en) * | 2003-06-20 | 2003-07-23 | Phico Therapeutics Ltd | Antimicrobial compositions and uses thereof |
| US7244612B2 (en) * | 2004-10-07 | 2007-07-17 | University Of Wyoming | Template reporter bacteriophage platform and multiple bacterial detection assays based thereon |
| GB0715416D0 (en) * | 2007-08-07 | 2007-09-19 | Phico Therapeutics Ltd | Modified bacteriophage |
| WO2009055697A1 (en) * | 2007-10-24 | 2009-04-30 | The Texas A & M University System | Chimeric phage tail proteins and uses thereof |
| GB201417810D0 (en) | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifying bacteriophage |
-
2014
- 2014-10-08 GB GBGB1417810.7A patent/GB201417810D0/en not_active Ceased
-
2015
- 2015-10-08 US US15/517,732 patent/US10953052B2/en active Active
- 2015-10-08 HU HUE15775457A patent/HUE047552T2/hu unknown
- 2015-10-08 DK DK15775457.3T patent/DK3201323T3/da active
- 2015-10-08 JP JP2017518842A patent/JP6748074B2/ja active Active
- 2015-10-08 AU AU2015329959A patent/AU2015329959B2/en active Active
- 2015-10-08 PT PT157754573T patent/PT3201323T/pt unknown
- 2015-10-08 HR HRP20200171TT patent/HRP20200171T1/hr unknown
- 2015-10-08 ES ES15775457T patent/ES2768773T3/es active Active
- 2015-10-08 LT LTEP15775457.3T patent/LT3201323T/lt unknown
- 2015-10-08 CA CA2963690A patent/CA2963690A1/en active Pending
- 2015-10-08 SI SI201531088T patent/SI3201323T1/sl unknown
- 2015-10-08 PL PL15775457T patent/PL3201323T3/pl unknown
- 2015-10-08 EP EP15775457.3A patent/EP3201323B1/en active Active
- 2015-10-08 WO PCT/EP2015/073296 patent/WO2016055586A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PT3201323T (pt) | 2020-02-14 |
| AU2015329959B2 (en) | 2021-11-04 |
| AU2015329959A9 (en) | 2019-08-01 |
| GB201417810D0 (en) | 2014-11-19 |
| DK3201323T3 (da) | 2020-02-03 |
| EP3201323A1 (en) | 2017-08-09 |
| JP2017529868A (ja) | 2017-10-12 |
| CA2963690A1 (en) | 2016-04-14 |
| HUE047552T2 (hu) | 2020-04-28 |
| HRP20200171T1 (hr) | 2020-05-15 |
| PL3201323T3 (pl) | 2020-05-18 |
| WO2016055586A9 (en) | 2019-02-07 |
| ES2768773T3 (es) | 2020-06-23 |
| US10953052B2 (en) | 2021-03-23 |
| WO2016055586A1 (en) | 2016-04-14 |
| SI3201323T1 (sl) | 2020-07-31 |
| AU2015329959A1 (en) | 2017-04-20 |
| US20170304379A1 (en) | 2017-10-26 |
| LT3201323T (lt) | 2020-04-10 |
| EP3201323B1 (en) | 2019-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6748074B2 (ja) | バクテリオファージの改変 | |
| JP7141756B2 (ja) | 異なる尾繊維を有する複数宿主域のバクテリオファージ | |
| JP2022058377A (ja) | 異なる尾繊維を有する複数宿主域のバクテリオファージ | |
| US20230416694A1 (en) | Modified bacteriophage | |
| US20170304378A1 (en) | Modifying bacteriophage using beta-galactosidase as a selectable marker | |
| JP7166244B2 (ja) | 改変バクテリオファージ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170914 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190222 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200714 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200806 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6748074 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |